Stock Research: Pfizer Limited

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Pfizer Limited

BSE:500680 INE182A01018
59
  • Value
    94
  • Growth
    33
  • Safety
    Safety
    31
  • Combined
    55
  • Sentiment
    60
  • 360° View
    360° View
    59
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Pfizer Limited is an India-based multinational pharmaceutical company. It focuses on Vaccines (Prevenar 13), Hospitals (advanced anti-infectives), Internal Medicine (respiratory, gastrointestinal, pain, cardiovascular), and Inflammation and Immunology (chronic autoimmune diseases, with brands like Enbrel). In the last fiscal year, the company had a market cap of $2848 million, profits of $166 million, and revenue of $267 million, with 1598 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 59 (better than 59% compared with alternatives), overall professional sentiment and financial characteristics for the stock Pfizer Limited are above average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Pfizer Limited. The consolidated Sentiment Rank has a good rank of 60, which means that professional investors are more optimistic about the stock than for 60% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 94 or better than 94% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 31, meaning that the share price of Pfizer Limited is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 33. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 16-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
31 55 39 33
Growth
33 15 37 25
Safety
Safety
94 76 72 65
Sentiment
60 43 57 14
360° View
360° View
59 44 59 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
81 87 95 87
Opinions Change
50 23 50 50
Pro Holdings
n/a 51 58 6
Market Pulse
43 12 3 11
Sentiment
60 43 57 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
31 55 39 33
Growth
33 15 37 25
Safety Safety
94 76 72 65
Combined
55 48 47 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
36 53 39 37
Price vs. Earnings (P/E)
11 19 14 16
Price vs. Book (P/B)
38 55 45 31
Dividend Yield
54 60 63 60
Value
31 55 39 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
37 39 42 16
Profit Growth
68 39 27 65
Capital Growth
8 7 96 42
Stock Returns
71 35 29 31
Growth
33 15 37 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
73 74 66 78
Refinancing
72 64 66 46
Liquidity
78 61 63 61
Safety Safety
94 76 72 65

Similar Stocks

Discover high‑ranked alternatives to Pfizer Limited and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.